Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo Rolls Out Lung, Breast Cancer Data for HER3-Directed ADC
March 22, 2023
- Mitsubishi Tanabe Files Canaglu OD Tablet Form in Japan
March 22, 2023
- Xtandi Plus Leuprolide Meet PIII Goal in Non-Metastatic Prostate Cancer: Astellas
March 20, 2023
- Takeda Updates Qdenga Peak Sales Estimate to US$1.6-2 Billion
March 17, 2023
- Fujifilm to Make Foray into Drug Discovery CRO Business
March 17, 2023
- Twymeeg No 1 in GP Promotion in January, Dayvigo Most Pitched for HP: Intage
March 17, 2023
- CSL R&D Head Touts Cost-Effectiveness of Hemophilia Gene Therapy Hemgenix
March 17, 2023
- Illumina Eyes Japan Launch of Comprehensive Genomic Profiling Test This Year
March 16, 2023
- Paxlovid to Enter Normal Distribution from March 22: Pfizer Japan
March 16, 2023
- Ono, PeptiDream in Deal for Macrocyclic Constrained Peptide Therapeutics
March 16, 2023
- Iron Solution MonoVer Now Available in Japan; Donepezil Patch, Cresemba to Hit Market in April
March 16, 2023
- Teijin Pharma Plans Pivot to Rare Diseases as Generics Eat into Feburic Sales
March 15, 2023
- Xtandi Hits Mark in China HSPC Study to Pave Way for Label Expansion
March 15, 2023
- Takeda’s Dengue Vaccine Approved in Brazil
March 15, 2023
- Eisai’s Leqembi Wins Coverage from US Veteran’s Body
March 15, 2023
- Bayer Setting Out to Cut Up to 480 Jobs as Xarelto Patent Cliff Looms: Employee
March 14, 2023
- Japan’s Non-COVID Jab Market to Surpass 180 Billion Yen by 2030: Fuji Keizai
March 14, 2023
- Moderna, Tohoku University Link Up for Next-Gen Healthcare
March 14, 2023
- Shionogi Inks Malaria Drug Collab with Nagasaki University, MMV
March 14, 2023
- Serious Side Effect Cases Total 8: Xocova Safety Update
March 13, 2023
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…